Ashley Bush

List of Publications by Year
in descending order

520	67,949	765 123	987 244
papers	citations	h-index	g-index

571	571	571	51389
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Connecting copper and cancer: from transition metal signalling to metalloplasia. Nature Reviews Cancer, 2022, 22, 102-113.	12.8	519
2	Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis. Cell Death and Differentiation, 2022, 29, 1187-1198.	5.0	63
3	Disruption of Hfe leads to skeletal muscle iron loading and reduction of hemoproteins involved in oxidative metabolism in a mouse model of hereditary hemochromatosis. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130082.	1.1	2
4	Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimerâ€™s disease. Proteome Science, 2022, 20, 2.	0.7	6
5	APOE Îµ2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimer's and Dementia, 2022, 18, 2151-2166.	0.4	16
6	Neuropathological Mechanisms of Î²-N-Methylamino-L-Alanine (BMAA) with a Focus on Iron Overload and Ferroptosis. Neurotoxicity Research, 2022, 40, 614-635.	1.3	2
7	Selenium mediates exercise-induced adult neurogenesis and reverses learning deficits induced by hippocampal injury and aging. Cell Metabolism, 2022, 34, 408-423.e8.	7.2	58
8	Does the FDAâ€approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?. Medical Journal of Australia, 2022, , .	0.8	1
9	The Neuroinflammatory Acute Phase Response in Parkinsonianâ€Related Disorders. Movement Disorders, 2022, 37, 993-1003.	2.2	8
10	Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12307.	1.2	14
11	Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion. Signal Transduction and Targeted Therapy, 2022, 7, 59.	7.1	88
12	BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells. Cell Death and Differentiation, 2022, 29, 1335-1348.	5.0	15
13	Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1541-1553.	2.9	5
14	Copper bis(thiosemicarbazone) complexes modulate Pâ€glycoprotein expression and function in human brain microvascular endothelial cells. Journal of Neurochemistry, 2022, , .	2.1	9
15	Selective ferroptosis vulnerability due to familial Alzheimerâ€™s disease presenilin mutations. Cell Death and Differentiation, 2022, 29, 2123-2136.	5.0	32
16	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. Biomedicines, 2022, 10, 1045.	1.4	1
17	Apolipoprotein E potently inhibits ferroptosis by blocking ferritinophagy. Molecular Psychiatry, 2022, , .	4.1	38
18	Comprehensive genetic analysis of the human lipidome identifies loci associated with lipid homeostasis with links to coronary artery disease. Nature Communications, 2022, 13, .	5.8	30

#	Article	IF	Citations
19	Acute phase markers in CSF reveal inflammatory changes in Alzheimerâ€™s disease that intersect with pathology, APOE Îµ4, sex and age. Progress in Neurobiology, 2021, 198, 101904.	2.8	25
20	Î²-amyloid: The known unknowns. Ageing Research Reviews, 2021, 65, 101212.	5.0	27
21	The essential elements of Alzheimerâ€™s disease. Journal of Biological Chemistry, 2021, 296, 100105.	1.6	140
22	Iron and Ferroptosis as Therapeutic Targets in Alzheimer's Disease. Neurotherapeutics, 2021, 18, 252-264.	2.1	55
23	Unblinded by the light: amyloidâ€related imaging abnormalities in Alzheimerâ€™s clinical trials. European Journal of Neurology, 2021, 28, e1.	1.7	16
24	An integrated mass spectrometry imaging and digital pathology workflow for objective detection of colorectal tumours by unique atomic signatures. Chemical Science, 2021, 12, 10321-10333.	3.7	7
25	Systematic Review: Quantitative Susceptibility Mapping (QSM) of Brain Iron Profile in Neurodegenerative Diseases. Frontiers in Neuroscience, 2021, 15, 618435.	1.4	83
26	Iron accumulation in skeletal muscles of old mice is associated with impaired regeneration after ischaemiaâ€“reperfusion damage. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 476-492.	2.9	17
27	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 443-468.	1.2	59
28	Development of Novel Therapeutics Targeting the Bloodâ€“Brain Barrier: From Barrier to Carrier. Advanced Science, 2021, 8, e2101090.	5.6	75
29	Zinc drives vasorelaxation by acting in sensory nerves, endothelium and smooth muscle. Nature Communications, 2021, 12, 3296.	5.8	25
30	The acute phase protein lactoferrin is a key feature of Alzheimerâ€™s disease and predictor of AÎ² burden through induction of APP amyloidogenic processing. Molecular Psychiatry, 2021, 26, 5516-5531.	4.1	29
31	From mouse to mouseâ€ear cress: Nanomaterials as vehicles in plant biotechnology. Exploration, 2021, 1, 9-20.	5.4	27
32	An Online, Person-Centered, Risk Factor Management Program to Prevent Cognitive Decline: Protocol for A Prospective Behavior-Modification Blinded Endpoint Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021, 83, 1603-1622.	1.2	5
33	Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease. Journal of Neurochemistry, 2021, 159, 804-825.	2.1	89
34	Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemiaâ€“Reperfusion Injury. Neurotherapeutics, 2021, 18, 2682-2691.	2.1	39
35	Copper and lipid metabolism: A reciprocal relationship. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129979.	1.1	26
36	Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy. Neurobiology of Disease, 2021, 159, 105509.	2.1	8

#	Article	IF	Citations
37	Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance. Alzheimer's and Dementia, 2021, 17, 1244-1256.	0.4	71
38	Ferroptosis and NRF2: an emerging battlefield in the neurodegeneration of Alzheimer's disease. Essays in Biochemistry, 2021, 65, 925-940.	2.1	57
39	Iron intake, brain iron, and Alzheimerâ€™s disease among communityâ€dwelling older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
40	Lipidomic signatures for APOE genotypes provides new insights about mechanisms of resilience in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
41	Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Molecular Psychiatry, 2020, 25, 2932-2941.	4.1	202
42	Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington's Disease. Neurotherapeutics, 2020, 17, 243-251.	2.1	15
43	Cu^{II}(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. British Journal of Pharmacology, 2020, 177, 656-667.	2.7	92
44	Preferential Neurodegeneration in the Dentate Gyrus by Amyloid Î²1â€“42-Induced Intracellular Zn2+Dysregulation and Its Defense Strategy. Molecular Neurobiology, 2020, 57, 1875-1888.	1.9	13
45	Regional iron distribution and soluble ferroprotein profiles in the healthy human brain. Progress in Neurobiology, 2020, 186, 101744.	2.8	25
46	Fibrillar Î±-synuclein toxicity depends on functional lysosomes. Journal of Biological Chemistry, 2020, 295, 17497-17513.	1.6	30
47	Blood-brain barrierâ€“penetrating siRNA nanomedicine for Alzheimerâ€™s disease therapy. Science Advances, 2020, 6, .	4.7	135
48	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. BMJ Open, 2020, 10, e040100.	0.8	11
49	Concordant peripheral lipidome signatures in two large clinical studies of Alzheimerâ€™s disease. Nature Communications, 2020, 11, 5698.	5.8	76
50	Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism. Scientific Reports, 2020, 10, 17631.	1.6	10
51	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimerâ€™s Disease Patients and Correlates with Cognitive Performance. Journal of Alzheimer's Disease, 2020, 77, 733-744.	1.2	7
52	Parkinsonism as a Third Wave of the COVID-19 Pandemic?. Journal of Parkinson's Disease, 2020, 10, 1343-1353.	1.5	50
53	S-Adenosylmethionine Rescues Cognitive Deficits in the rTg4510 Animal Model by Stabilizing Protein Phosphatase 2A and Reducing Phosphorylated Tau. Journal of Alzheimer's Disease, 2020, 77, 1705-1715.	1.2	11
54	Deferiprone to delay dementia (the 3D trial). Alzheimer's and Dementia, 2020, 16, e044107.	0.4	8

#	Article	IF	Citations
55	Limited cerebral microbleeds effect on regional magnetic susceptibility measured by MRI. Alzheimer's and Dementia, 2020, 16, e044125.	0.4	0
56	Restricted Effect of Cerebral Microbleeds on Regional Magnetic Susceptibility. Journal of Alzheimer's Disease, 2020, 76, 571-577.	1.2	6
57	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 303-315.	1.2	23
58	Adrenergic Î² receptor activation reduces amyloid Î²1-42-mediated intracellular Zn2+ toxicity in dentate granule cells followed by rescuing impairment of dentate gyrus LTP. NeuroToxicology, 2020, 79, 177-183.	1.4	5
59	Alzheimer risk factors age and female sex induce cortical AÎ² aggregation by raising extracellular zinc. Molecular Psychiatry, 2020, 25, 2728-2741.	4.1	16
60	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12005.	1.2	35
61	Iron chelation by deferiprone does not rescue the Niemann-Pick Disease Type C1 mouse model. BioMetals, 2020, 33, 87-95.	1.8	11
62	The ubiquitin proteasome system and schizophrenia. Lancet Psychiatry,the, 2020, 7, 528-537.	3.7	43
63	Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying Î²-amyloid pathology. Neurobiology of Disease, 2020, 139, 104810.	2.1	24
64	Zinc Transporter-3 Knockout Mice Demonstrate Age-Dependent Alterations in the Metalloproteome. International Journal of Molecular Sciences, 2020, 21, 839.	1.8	8
65	Amyloidogenic processing of Alzheimerâ€™s disease Î²-amyloid precursor protein induces cellular iron retention. Molecular Psychiatry, 2020, 25, 1958-1966.	4.1	52
66	Changes in ferrous iron and glutathione promote ferroptosis and frailty in aging Caenorhabditis elegans. ELife, 2020, 9, .	2.8	68
67	Cellular Senescence and Iron Dyshomeostasis in Alzheimerâ€™s Disease. Pharmaceuticals, 2019, 12, 93.	1.7	68
68	Redox active metals in neurodegenerative diseases. Journal of Biological Inorganic Chemistry, 2019, 24, 1141-1157.	1.1	60
69	Amyloid Precursor Protein Mediates Neuronal Protection from Rotenone Toxicity. Molecular Neurobiology, 2019, 56, 5471-5482.	1.9	25
70	Difference in ability for extracellular Zn2+ influx between human and rat amyloid Î²1-42 and its significance. NeuroToxicology, 2019, 72, 1-5.	1.4	6
71	<scp>l</scp>â€3,4â€dihydroxyphenylalanine (<scp>l</scp>â€DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alphaâ€synuclein mouse models of Parkinson's disease. Journal of Neurochemistry, 2019, 150, 88-106.	2.1	24
72	Decreasing iron neurotoxicity in pantothenate kinase-associated neurodegeneration. Lancet Neurology, The, 2019, 18, 616-617.	4.9	3

#	Article	IF	Citations
73	Extracellular Zn2+-independently attenuated LTP by human amyloid Î²1-40 and rat amyloid Î²1-42. Biochemical and Biophysical Research Communications, 2019, 514, 888-892.	1.0	9
74	In vivo synaptic activity-independent co-uptakes of amyloid Î²1â€“42 and Zn2+ into dentate granule cells in the normal brain. Scientific Reports, 2019, 9, 6498.	1.6	14
75	Mice overexpressing hepcidin suggest ferroportin does not play a major role in Mn homeostasis. Metallomics, 2019, 11, 959-967.	1.0	7
76	Blood and brain protein levels of ubiquitin-conjugating enzyme E2K (UBE2K) are elevated in individuals with schizophrenia. Journal of Psychiatric Research, 2019, 113, 51-57.	1.5	14
77	The Effects of Clioquinol on P-glycoprotein Expression and Biometal Distribution in the Mouse Brain Microvasculature. Journal of Pharmaceutical Sciences, 2019, 108, 2247-2255.	1.6	5
78	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimerâ€™s disease. Science Advances, 2019, 5, eaau7220.	4.7	59
79	Zn-DTSM, A Zinc Ionophore with Therapeutic Potential for Acrodermatitis Enteropathica?. Nutrients, 2019, 11, 206.	1.7	1
80	Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia. Scientific Reports, 2019, 9, 2307.	1.6	31
81	Axonal dispatch of iron in neuronal signaling. Nature Chemical Biology, 2019, 15, 1135-1136.	3.9	6
82	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. Neurotherapeutics, 2019, 16, 192-202.	2.1	69
83	Redox Modulating Factors Affect Longevity Regulation in Rotifers. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 811-814.	1.7	8
84	Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying Î²-amyloid pathology. Neurobiology of Disease, 2019, 124, 335-339.	2.1	39
85	Molecular Mechanisms of Glutaredoxin Enzymes: Versatile Hubs for Thiolâ€“Disulfide Exchange between Protein Thiols and Glutathione. Journal of Molecular Biology, 2019, 431, 158-177.	2.0	59
86	Amyloid Î²1â€“42-Induced Rapid Zn2+ Influx into Dentate Granule Cells Attenuates Maintained LTP Followed by Retrograde Amnesia. Molecular Neurobiology, 2019, 56, 5041-5050.	1.9	5
87	Treating Alzheimer's disease by targeting iron. British Journal of Pharmacology, 2019, 176, 3622-3635.	2.7	71
88	Parkinson's disease prevalence and the association with rurality and agricultural determinants. Parkinsonism and Related Disorders, 2019, 61, 198-202.	1.1	13
89	Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration. Free Radical Biology and Medicine, 2019, 133, 221-233.	1.3	312
90	Zinc in Neurodegeneration. , 2019, , 201-228.		0

#	Article	IF	Citations
91	Novel Defense by Metallothionein Induction Against Cognitive Decline: From Amyloid Î²1â€“42-Induced Excess Zn2+ to Functional Zn2+ Deficiency. Molecular Neurobiology, 2018, 55, 7775-7788.	1.9	23
92	Ionophore and Biometal Modulation of P-glycoprotein Expression and Function in Human Brain Microvascular Endothelial Cells. Pharmaceutical Research, 2018, 35, 83.	1.7	16
93	Cognitive gene risk profile for the prediction of cognitive decline in presymptomatic Alzheimerâ€™s disease. Personalized Medicine in Psychiatry, 2018, 7-8, 14-20.	0.1	13
94	Iron as a therapeutic target for Parkinson's disease. Movement Disorders, 2018, 33, 568-574.	2.2	94
95	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE Îµ4-positive cognitively normal adults with high Aî²-amyloid burden. Scientific Reports, 2018, 8, 2034.	1.6	31
96	Alzheimerâ€™s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategiesâ€”Gains from AIBL and DIAN Cohort Studies. Journal of Alzheimer's Disease, 2018, 62, 965-992.	1.2	96
97	Metals and Alzheimerâ€™s Disease: How Far Have We Come in the Clinic?. Journal of Alzheimer's Disease, 2018, 62, 1369-1379.	1.2	133
98	Elevated plasma ferritin in elderly individuals with high neocortical amyloid-Î² load. Molecular Psychiatry, 2018, 23, 1807-1812.	4.1	49
99	Evidence that iron accelerates Alzheimerâ€™s pathology: a CSF biomarker study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 456-460.	0.9	66
100	Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. Redox Biology, 2018, 14, 100-115.	3.9	261
101	What can predict and prevent the long-term use of benzodiazepines?. Journal of Psychiatric Research, 2018, 97, 94-100.	1.5	18
102	Glutaredoxins employ parallel monothiolâ€“dithiol mechanisms to catalyze thiolâ€“disulfide exchanges with protein disulfides. Chemical Science, 2018, 9, 1173-1183.	3.7	32
103	Overcoming the Bloodâ€“Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Advanced Materials, 2018, 30, e1801362.	11.1	415
104	A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging. Lecture Notes in Computer Science, 2018, , 65-72.	1.0	1
105	Manganese causes neurotoxic iron accumulation via translational repression of amyloid precursor protein and Hâ€Ferritin. Journal of Neurochemistry, 2018, 147, 831-848.	2.1	52
106	Association of metals with the risk and clinical characteristics of Parkinson's disease. Parkinsonism and Related Disorders, 2018, 55, 117-121.	1.1	29
107	Ablation of tau causes an olfactory deficit in a murine model of Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 57.	2.4	11
108	Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. Acta Neuropsychiatrica, 2018, 30, 334-341.	1.0	16

#	Article	IF	Citations
109	Adrenergic Î² receptor activation in the basolateral amygdala, which is intracellular Zn2+-dependent, rescues amyloid Î²1-42-induced attenuation of dentate gyrus LTP. Neurochemistry International, 2018, 120, 43-48.	1.9	5
110	Targeting metals rescues the phenotype in an animal model of tauopathy. Metallomics, 2018, 10, 1339-1347.	1.0	20
111	Marked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout Mice. Neurotherapeutics, 2018, 15, 1055-1062.	2.1	53
112	Generation and characterization of human induced pluripotent stem cell lines from a familial Alzheimer's disease PSEN1 A246E patient and a non-demented family member bearing wild-type PSEN1. Stem Cell Research, 2018, 31, 227-230.	0.3	11
113	Iron and Alzheimerâ€™s Disease: An Update on Emerging Mechanisms. Journal of Alzheimer's Disease, 2018, 64, S379-S395.	1.2	205
114	Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychological Medicine, 2017, 47, 866-876.	2.7	88
115	Ferroptosis and cell death mechanisms in Parkinson's disease. Neurochemistry International, 2017, 104, 34-48.	1.9	260
116	Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau. Journal of Alzheimer's Disease, 2017, 56, 849-860.	1.2	23
117	Selenium Levels in Serum, Red Blood Cells, and Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients: A Report from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL). Journal of Alzheimer's Disease, 2017, 57, 183-193.	1.2	54
118	Whole-brain metallomic analysis of the common marmoset (Callithrix jacchus). Metallomics, 2017, 9, 411-423.	1.0	9
119	The APOE Îµ4 Allele Is Associated with Lower Selenium Levels in the Brain: Implications for Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2017, 8, 1459-1464.	1.7	48
120	Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 60-72.	1.2	29
121	Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry. Analytical Chemistry, 2017, 89, 6136-6145.	3.2	70
122	Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-Îµ4 Carriers. JAMA Neurology, 2017, 74, 122.	4.5	61
123	Tat-haFGF 14â€“154 Upregulates ADAM10 to Attenuate the Alzheimer Phenotype of APP/PS1 Mice through the PI3K-CREB-IRE1Î±/XBP1 Pathway. Molecular Therapy - Nucleic Acids, 2017, 7, 439-452.	2.3	24
124	Novel in vivo experimental viability assays with high sensitivity and throughput capacity using a bdelloid rotifer. Ecotoxicology and Environmental Safety, 2017, 144, 115-122.	2.9	15
125	Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. Journal of Magnetic Resonance Imaging, 2017, 46, 951-971.	1.9	199
126	Oxidation of Iron under Physiologically Relevant Conditions in Biological Fluids from Healthy and Alzheimerâ€™s Disease Subjects. ACS Chemical Neuroscience, 2017, 8, 731-736.	1.7	3

#	Article	IF	Citations
127	The Copper bis(thiosemicarbazone) Complex CuII(atsm) Is Protective Against Cerebral Ischemia Through Modulation of the Inflammatory Milieu. Neurotherapeutics, 2017, 14, 519-532.	2.1	42
128	Amyloid Precursor Protein Haploinsufficiency Preferentially Mediates Brain Iron Accumulation in Mice Transgenic for The Huntingtonâ€™s Disease Mutation. Journal of Huntington's Disease, 2017, 6, 115-125.	0.9	5
129	Reduction potentials of protein disulfides and catalysis of glutathionylation and deglutathionylation by glutaredoxin enzymes. Biochemical Journal, 2017, 474, 3799-3815.	1.7	18
130	Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell, 2017, 171, 273-285.	13.5	4,081
131	A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of Î²-amyloid load in an AD cohort. Scientific Reports, 2017, 7, 14057.	1.6	22
132	No Genetic Overlap Between Circulating Iron Levels and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 59, 85-99.	1.2	10
133	Nanoscale Imaging Reveals Big Role for Iron in Alzheimerâ€™s Disease. Cell Chemical Biology, 2017, 24, 1192-1194.	2.5	13
134	Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Molecular Psychiatry, 2017, 22, 1520-1530.	4.1	449
135	Accelerated kindling epileptogenesis in Tg4510 tau transgenic mice, but not in tau knockout mice. Epilepsia, 2017, 58, e136-e141.	2.6	30
136	Imaging Metals in Brain Tissue by Laser Ablation - Inductively Coupled Plasma - Mass Spectrometry (LA-ICP-MS). Journal of Visualized Experiments, 2017, , .	0.2	22
137	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimerâ€™s Disease Pathology Between Three Independent Assay Platforms. Journal of Alzheimer's Disease, 2017, 61, 169-183.	1.2	21
138	[P1â€“169]: LACTOFERRIN IS AN IRON TRANSPORTER AND KEY INNATE IMMUNE RESPONSE PROTEIN THAT DIRECTLY BINDS AMYLOIDâ€Î²² PRECURSOR PROTEIN TO PROMOTE AMYLOIDOGENIC PROCESSING. Alzheimer's and Dementia, 2017, 13, P308.	0.4	0
139	A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping. , 2017, , .		3
140	The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2017, 5, 53.	2.4	77
141	Extracellular Zn²⁺ Is Essential for Amyloid Î²_{1â€“42}-Induced Cognitive Decline in the Normal Brain and Its Rescue. Journal of Neuroscience, 2017, 37, 7253-7262.	1.7	47
142	Glutathione peroxidase 4: a new player in neurodegeneration?. Molecular Psychiatry, 2017, 22, 328-335.	4.1	196
143	Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Molecular Psychiatry, 2017, 22, 396-406.	4.1	66
144	[P3â€“153]: THE INFLUENCE OF AMYLOIDâ€Î² PRECURSOR PROTEIN PROTEOLYTIC PROCESSING ON NEURONAL IRON HOMEOSTASIS. Alzheimer's and Dementia, 2017, 13, P993.	0.4	0

#	Article	IF	Citations
145	[P3â€“243]: A MASS SPECTROMETRYâ€BASED DISCOVERY AND REPLICATION OF A MULTIâ€ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1033.	0.4	0
146	[P1â€“444]: QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN Aî²+ ELDERLY CONTROLS AND ALZHEIMER's DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P454.	0.4	2
147	Cerebral quantitative susceptibility mapping predicts amyloid-î²-related cognitive decline. Brain, 2017, 140, 2112-2119.	3.7	213
148	The Role of Selenium in Neurodegenerative Diseases. , 2017, , 35-49.		4
149	Metalloregulation of Protein Clearance: New Therapeutic Avenues for Neurodegenerative Diseases. , 2017, , 363-376.		0
150	Editorial: The CB2 Cannabinoid System: A New Strategy in Neurodegenerative Disorder and Neuroinflammation. Frontiers in Neuroscience, 2017, 11, 196.	1.4	19
151	Targeting Transition Metals forÂNeuroprotection inÂAlzheimerâ€™s Disease. , 2017, , 193-215.		2
152	S-sulfocysteine/NMDA receptorâ€“dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. Journal of Clinical Investigation, 2017, 127, 4365-4378.	3.9	62
153	Metallo-pathways to Alzheimer's disease: lessons from genetic disorders of copper trafficking. Metallomics, 2016, 8, 831-839.	1.0	35
154	Dementia Research Australia: the Australian Dementia Research Development Fellowship Program. Journal of Molecular Neuroscience, 2016, 60, 277-278.	1.1	6
155	Overexpression of Metallothionein-1 Modulates the Phenotype of the Tg2576 Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 81-95.	1.2	17
156	Iron Regulates Apolipoprotein E Expression and Secretion in Neurons and Astrocytes. Journal of Alzheimer's Disease, 2016, 51, 471-487.	1.2	37
157	Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinsonâ€™s substantia nigra. Signal Transduction and Targeted Therapy, 2016, 1, 16015.	7.1	36
158	Delivery of Fluorescent Nanoparticles to the Brain. Journal of Molecular Neuroscience, 2016, 60, 405-409.	1.1	16
159	The Complex Role of Apolipoprotein E in Alzheimerâ€™s Disease: an Overview and Update. Journal of Molecular Neuroscience, 2016, 60, 325-335.	1.1	64
160	Context matters: communicating the need for biomarkers for mental illnesses to the general public. Australasian Psychiatry, 2016, 24, 512-512.	0.4	0
161	Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. Journal of Neurochemistry, 2016, 139, 179-197.	2.1	417
162	Amyloid Î² attenuates metabotropic zinc sensing receptor, <scp>mZnR</scp>/<scp>GPR</scp>39, dependent Ca²⁺, <scp>ERK</scp>1/2 and Clusterin signaling in neurons. Journal of Neurochemistry, 2016, 139, 221-233.	2.1	26

#	Article	IF	Citations
163	Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 2016, 87, 1093-1101.	1.5	26
164	Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3Î² Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson's Disease. Neurodegenerative Diseases, 2016, 16, 357-369.	0.8	18
165	Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. NPJ Schizophrenia, 2016, 2, 16002.	2.0	47
166	ÏŧXANES: In vivo imaging of metal-protein coordination environments. Scientific Reports, 2016, 6, 20350.	1.6	37
167	Rubidium and potassium levels are altered in Alzheimerâ€™s disease brain and blood but not in cerebrospinal fluid. Acta Neuropathologica Communications, 2016, 4, 119.	2.4	39
168	Laser ablation-inductively coupled plasma-mass spectrometry imaging of white and gray matter iron distribution in Alzheimer's disease frontal cortex. NeuroImage, 2016, 137, 124-131.	2.1	57
169	Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 18-26.	1.2	30
170	Neurological Dysfunction in Early Maturity of a Model for Niemannâ€“Pick C1 Carrier Status. Neurotherapeutics, 2016, 13, 614-622.	2.1	17
171	Amyloid-Î² Peptide AÎ²3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons. Journal of Biological Chemistry, 2016, 291, 6134-6145.	1.6	74
172	A Mixed Methods Approach to Identify Cognitive Warning Signs for Suicide Attempts. Archives of Suicide Research, 2016, 20, 528-538.	1.2	11
173	High-resolution complementary chemical imaging of bio-elements in Caenorhabditis elegans. Metallomics, 2016, 8, 156-160.	1.0	22
174	Lead and manganese levels in serum and erythrocytes in Alzheimer's disease and mild cognitive impairment: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Metallomics, 2016, 8, 628-632.	1.0	30
175	Effects of Neonatal Iron Feeding and Chronic Clioquinol Administration on the Parkinsonian Human A53T Transgenic Mouse. ACS Chemical Neuroscience, 2016, 7, 360-366.	1.7	32
176	Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice. ACS Chemical Neuroscience, 2016, 7, 119-129.	1.7	64
177	High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer's Disease. Current Alzheimer Research, 2016, 13, 787-799.	0.7	23
178	Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases. Current Topics in Medicinal Chemistry, 2016, 16, 3058-3068.	1.0	27
179	Ferritin levels in the cerebrospinal fluid predict Alzheimerâ€™s disease outcomes and are regulated by APOE. Nature Communications, 2015, 6, 6760.	5.8	240
180	Selenium, selenoproteins and neurodegenerative diseases. Metallomics, 2015, 7, 1213-1228.	1.0	210

#	Article	IF	Citations
181	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Psychiatry Research, 2015, 230, 982-983.	1.7	11
182	Direct in vivo imaging of ferrous iron dyshomeostasis in ageing Caenorhabditis elegans. Chemical Science, 2015, 6, 2952-2962.	3.7	86
183	Visualising mouse neuroanatomy and function by metal distribution using laser ablation-inductively coupled plasma-mass spectrometry imaging. Chemical Science, 2015, 6, 5383-5393.	3.7	69
184	Metal chaperones prevent zinc-mediated cognitive decline. Neurobiology of Disease, 2015, 81, 196-202.	2.1	47
185	Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease. Redox Biology, 2015, 4, 363-374.	3.9	31
186	Decreased Plasma Iron in Alzheimerâ€™s Disease Is Due to Transferrin Desaturation. ACS Chemical Neuroscience, 2015, 6, 398-402.	1.7	75
187	High Order W02-Reactive Stable Oligomers of Amyloid-Î² are Produced in vivo and in vitro via Dialysis and Filtration of Synthetic Amyloid-Î² Monomer. Journal of Alzheimer's Disease, 2015, 44, 69-78.	1.2	2
188	Parkinson's Disease Iron Deposition Caused by Nitric Oxide-Induced Loss of Î²-Amyloid Precursor Protein. Journal of Neuroscience, 2015, 35, 3591-3597.	1.7	109
189	Is early-life iron exposure critical in neurodegeneration?. Nature Reviews Neurology, 2015, 11, 536-544.	4.9	86
190	Zinc affects the proteolytic stability of Apolipoprotein E in an isoform-dependent way. Neurobiology of Disease, 2015, 81, 38-48.	2.1	16
191	Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimer's Research and Therapy, 2015, 7, 16.	3.0	22
192	A mouse model of Alzheimer's disease displays increased susceptibility to kindling and seizureâ€associated death. Epilepsia, 2015, 56, e73-7.	2.6	35
193	Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiology of Disease, 2015, 81, 168-175.	2.1	73
194	Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimerâ€™s Disease. ACS Medicinal Chemistry Letters, 2015, 6, 1025-1029.	1.3	41
195	Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of Î²-Amyloid Toxicity and Are Mediated by Tau. Neurotherapeutics, 2015, 12, 862-873.	2.1	50
196	Traumatic brain injury induces elevation of Co in the human brain. Metallomics, 2015, 7, 66-70.	1.0	11
197	Biometals and Their Therapeutic Implications in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 109-120.	2.1	109
198	Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 57, 69-75.	2.5	29

#	Article	IF	Citations
199	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimerâ€™s Disease: A Preliminary Study. PLoS ONE, 2014, 9, e86498.	1.1	75
200	Metals and cholesterol: two sides of the same coin in AlzheimerÃ¢â‚¬â„¢s disease pathology. Frontiers in Aging Neuroscience, 2014, 6, 91.	1.7	36
201	ÃŽÂ²-amyloid in biological samples: not all AÃŽÂ² detection methods are created equal. Frontiers in Aging Neuroscience, 2014, 6, 203.	1.7	3
202	Copper-uptake is critical for the down regulation of synapsin and dynamin induced by neocuproine: modulation of synaptic activity in hippocampal neurons. Frontiers in Aging Neuroscience, 2014, 6, 319.	1.7	16
203	Copper: from neurotransmission to neuroproteostasis. Frontiers in Aging Neuroscience, 2014, 6, 143.	1.7	112
204	A novel approach to rapidly prevent ageâ€related cognitive decline. Aging Cell, 2014, 13, 351-359.	3.0	46
205	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). International Psychogeriatrics, 2014, 26, 543-554.	0.6	37
206	Associations between gonadotropins, testosterone and Î² amyloid in men at risk of Alzheimerâ€™s disease. Molecular Psychiatry, 2014, 19, 69-75.	4.1	98
207	Phosphorylation of Amyloid Precursor Protein at Threonine 668 Is Essential for Its Copper-responsive Trafficking in SH-SY5Y Neuroblastoma Cells. Journal of Biological Chemistry, 2014, 289, 11007-11019.	1.6	41
208	Altered transition metal homeostasis in Niemannâ€“Pick disease, type C1. Metallomics, 2014, 6, 542-553.	1.0	26
209	Decreased serum zinc is an effect of ageing and not Alzheimer's disease. Metallomics, 2014, 6, 1216-1219.	1.0	34
210	Quantitation and localization of intracellular redox active metals by X-ray fluorescence microscopy in cortical neurons derived from APP and APLP2 knockout tissue. Metallomics, 2014, 6, 1894-1904.	1.0	21
211	The effect of paraformaldehyde fixation and sucrose cryoprotection on metal concentration in murine neurological tissue. Journal of Analytical Atomic Spectrometry, 2014, 29, 565-570.	1.6	45
212	An ironâ€“dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chemical Science, 2014, 5, 2160-2169.	3.7	98
213	Biological metals and metal-targeting compounds in major neurodegenerative diseases. Chemical Society Reviews, 2014, 43, 6727-6749.	18.7	417
214	Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurology, 2014, 83, 1345-1352.	1.5	58
215	A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe2+ under physiologically relevant conditions. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 3299-3310.	1.1	24
216	Altered selenium status in Huntington's disease: Neuroprotection by selenite in the N171-82Q mouse model. Neurobiology of Disease, 2014, 71, 34-42.	2.1	39

#	Article	IF	Citations
217	Response to Comment on Moore et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care 2013;36:2981â€“2987. Diabetes Care, 2014, 37, e151-e151.	4.3	4
218	Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinsonâ€™s disease. Molecular Neurodegeneration, 2014, 9, 27.	4.4	60
219	Motor and cognitive deficits in aged tau knockout mice in two background strains. Molecular Neurodegeneration, 2014, 9, 29.	4.4	117
220	Neuroprotective peptideâ€“macrocycle conjugates reveal complex structureâ€“activity relationships in their interactions with amyloid Î². Metallomics, 2014, 6, 1931-1940.	1.0	20
221	Oral Treatment with Cu(II)(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2014, 34, 8021-8031.	1.7	161
222	An anemia of Alzheimer's disease. Molecular Psychiatry, 2014, 19, 1227-1234.	4.1	114
223	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. Journal of Alzheimer's Disease, 2014, 39, 661-668.	1.2	76
224	Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiology of Aging, 2014, 35, S74-S78.	1.5	251
225	Ceruloplasmin and Î²-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. Free Radical Biology and Medicine, 2014, 69, 331-337.	1.3	49
226	An increased neutrophilâ€“lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. Journal of Neuroimmunology, 2014, 273, 65-71.	1.1	87
227	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 53-61.	0.4	114
228	A blood-based predictor for neocortical AÎ² burden in Alzheimerâ€™s disease: results from the AIBL study. Molecular Psychiatry, 2014, 19, 519-526.	4.1	108
229	Plasma Amyloid-Î² Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. Journal of Alzheimer's Disease, 2014, 40, 95-104.	1.2	41
230	A review of ÃŽÂ²-amyloid neuroimaging in Alzheimer's disease. Frontiers in Neuroscience, 2014, 8, 327.	1.4	76
231	The Efficacy of AdjunctiveN-Acetylcysteine in Major Depressive Disorder. Journal of Clinical Psychiatry, 2014, 75, 628-636.	1.1	142
232	P4-369: REVISITING THE ALZHEIMER'S AND PARKINSONISM PHENOTYPES OF TAU KO MICE: POTENTIAL GENETIC BACKGROUND EFFECT. , 2014, 10, P924-P924.		0
233	The Clinical Implications of Impaired Zinc Signaling in the Brain. , 2014, , 183-196.		1
234	Î²-Amyloid Precursor Protein Does Not Possess Ferroxidase Activity but Does Stabilize the Cell Surface Ferrous Iron Exporter Ferroportin. PLoS ONE, 2014, 9, e114174.	1.1	130

#	Article	IF	Citations
235	Amyloid Î²-Mediated Zn2+ Influx into Dentate Granule Cells Transiently Induces a Short-Term Cognitive Deficit. PLoS ONE, 2014, 9, e115923.	1.1	33
236	Metal dyshomeostasis and oxidative stress in Alzheimerâ€™s disease. Neurochemistry International, 2013, 62, 540-555.	1.9	376
237	Increasing Intracellular Bioavailable Copper Selectively Targets Prostate Cancer Cells. ACS Chemical Biology, 2013, 8, 1621-1631.	1.6	115
238	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimerâ€™s disease. BMC Psychology, 2013, 1, 30.	0.9	153
239	Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care, 2013, 36, 2981-2987.	4.3	308
240	Meta-Analysis of Serum Non-Ceruloplasmin Copper in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 809-822.	1.2	101
241	Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics, 2013, 5, 1656.	1.0	39
242	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 171-182.	1.2	46
243	Metallostasis in Alzheimer's disease. Free Radical Biology and Medicine, 2013, 62, 76-89.	1.3	297
244	Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Annals of Neurology, 2013, 73, 554-559.	2.8	218
245	Direct in vivo imaging of essential bioinorganics in Caenorhabditis elegans. Metallomics, 2013, 5, 627.	1.0	40
246	The effect of dopamine on MPTP-induced rotarod disability. Neuroscience Letters, 2013, 543, 105-109.	1.0	25
247	Physical activity and amyloid-Î² plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Molecular Psychiatry, 2013, 18, 875-881.	4.1	185
248	BDNF Val66Met, AÎ² amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	1.5	109
249	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-Î². Journal of Alzheimer's Disease, 2013, 34, 861-871.	1.2	42
250	Links between copper and cholesterol in Alzheimer's disease. Frontiers in Physiology, 2013, 4, 111.	1.3	35
251	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). Archives of Clinical Neuropsychology, 2013, 28, 320-330.	0.3	90
252	Cognitive Decline in Adults with Amnestic Mild Cognitive Impairment and High Amyloid-Î²: Prodromal Alzheimer's Disease?. Journal of Alzheimer's Disease, 2013, 33, 1167-1176.	1.2	34

#	Article	IF	Citations
253	A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Australian and New Zealand Journal of Psychiatry, 2013, 47, 564-568.	1.3	50
254	Amine oxidase activity of Î²-amyloid precursor protein modulates systemic and local catecholamine levels. Molecular Psychiatry, 2013, 18, 245-254.	4.1	14
255	Cognitive consequences of high AÎ² amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimerâ€™s disease.. Neuropsychology, 2013, 27, 322-332.	1.0	33
256	Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 2013;36:2981â€“2987. Diabetes Care, 2013, 36, 3850-3850.	4.3	10
257	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid-Î². Journal of Alzheimer's Disease, 2013, 33, 675-679.	1.2	62
258	Iron Accumulates in Huntingtonâ€™s Disease Neurons: Protection by Deferoxamine. PLoS ONE, 2013, 8, e77023.	1.1	119
259	Deserves a hearing? A case report of remitting tinnitus with N-acetyl cysteine. African Journal of Psychiatry, 2013, 16, 238, 240.	0.1	1
260	A delicate balance: Iron metabolism and diseases of the brain. Frontiers in Aging Neuroscience, 2013, 5, 34.	1.7	314
261	Copper Status in Alzheimerâ€™s Disease and Other Neurodegenerative Disorders 2013. International Journal of Alzheimer's Disease, 2013, 2013, 1-2.	1.1	4
262	Decreased Copper in Alzheimerâ€™s Disease Brain Is Predominantly in the Soluble Extractable Fraction. International Journal of Alzheimer's Disease, 2013, 2013, 1-7.	1.1	36
263	Presenilin Promotes Dietary Copper Uptake. PLoS ONE, 2013, 8, e62811.	1.1	25
264	Clioquinol Synergistically Augments Rescue by Zinc Supplementation in a Mouse Model of Acrodermatitis Enteropathica. PLoS ONE, 2013, 8, e72543.	1.1	15
265	The Role of the Plasma Membrane Redox System in the Pathogenesis of Alzheimerâ€™s Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 55-69.	0.4	0
266	Alterations in Brain Transition Metals in Huntington Disease. Archives of Neurology, 2012, 69, 887-93.	4.9	129
267	P2X7 Receptor-mediated Scavenger Activity of Mononuclear Phagocytes toward Non-opsonized Particles and Apoptotic Cells Is Inhibited by Serum Glycoproteins but Remains Active in Cerebrospinal Fluid. Journal of Biological Chemistry, 2012, 287, 17318-17330.	1.6	23
268	Caenorhabditis elegans Maintains Highly Compartmentalized Cellular Distribution of Metals and Steep Concentration Gradients of Manganese. PLoS ONE, 2012, 7, e32685.	1.1	47
269	PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 211-219.	0.9	57
270	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. International Psychogeriatrics, 2012, 24, 197-204.	0.6	39

#	Article	IF	Citations
271	Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of synthetic ceramide analogues. Clinical Science, 2012, 122, 409-420.	1.8	6
272	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Archives of Neurology, 2012, 69, 1318.	4.9	348
273	Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Psychiatry and Clinical Neurosciences, 2012, 66, 514-517.	1.0	45
274	â€œThe Sound of Fearâ€: Assessing vocal fundamental frequency as a physiological indicator of social anxiety disorder. Journal of Anxiety Disorders, 2012, 26, 811-822.	1.5	37
275	Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 132-135.	2.5	26
276	The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinsonâ€™s disease. Journal of Experimental Medicine, 2012, 209, 837-854.	4.2	151
277	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. BMC Medicine, 2012, 10, 91.	2.3	81
278	Translating the Rosetta Stone of N-Acetylcysteine. Biological Psychiatry, 2012, 71, 935-936.	0.7	20
279	Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nature Medicine, 2012, 18, 291-295.	15.2	491
280	Characterization of the role of the antioxidant proteins metallothioneins 1 and 2 in an animal model of Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2012, 69, 3665-3681.	2.4	27
281	Characterization of the role of metallothionein-3 in an animal model of Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2012, 69, 3683-3700.	2.4	45
282	Utility of an improved model of amyloid-beta (AÎ²1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimerâ€™s disease. Molecular Neurodegeneration, 2012, 7, 57.	4.4	188
283	Metal Chaperones: A Holistic Approach to the Treatment of Alzheimerâ€™s Disease. Frontiers in Psychiatry, 2012, 3, 15.	1.3	20
284	The Metal Theory of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S277-S281.	1.2	214
285	The role of metallobiology and amyloidâ€Î²2 peptides in Alzheimerâ€™s disease. Journal of Neurochemistry, 2012, 120, 149-166.	2.1	233
286	Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Radical Biology and Medicine, 2012, 52, 298-302.	1.3	144
287	Rapid Generation of Dityrosine Cross-linked AÎ² Oligomers via Cu-Redox Cycling. Methods in Molecular Biology, 2012, 849, 3-10.	0.4	6
288	Copper and Alzheimer Disease: The Good, the Bad and the Ugly. , 2012, , 609-645.		0

#	Article	IF	Citations
289	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. Journal of Alzheimer's Disease, 2011, 27, 909-922.	1.2	83
290	The Neurophysiology and Pathology of Brain Zinc. Journal of Neuroscience, 2011, 31, 16076-16085.	1.7	291
291	Chapter 8. Biological Metals: Metallostasis and Alzheimer's Disease. RSC Drug Discovery Series, 2011, , 152-173.	0.2	0
292	N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. Neuroscience Letters, 2011, 499, 149-153.	1.0	75
293	The plasma membrane redox system in Alzheimer's disease. Experimental Neurology, 2011, 228, 9-14.	2.0	8
294	Copper Modulation as a Therapy for Alzheimer's Disease?. International Journal of Alzheimer's Disease, 2011, 2011, 1-5.	1.1	10
295	N-acetylcysteine for major depressive episodes in bipolar disorder. Revista Brasileira De Psiquiatria, 2011, 33, 374-378.	0.9	99
296	GSK-3 in Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	1.1	119
297	A Copper Binding Site within the Pathological Conformer Epitope of Mutant SOD1. Frontiers in Neuroscience, 2011, 5, 97.	1.4	3
298	Disturbed Copper Bioavailability in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-5.	1.1	28
299	Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2011, 6, e17669.	1.1	115
300	The Alzheimerâ€™s therapeutic PBT2 promotes amyloidâ€Î²2 degradation and GSK3 phosphorylation via a metal chaperone activity. Journal of Neurochemistry, 2011, 119, 220-230.	2.1	167
301	Dimensions of improvement in a clinical trial ofN-acetyl cysteine for bipolar disorder. Acta Neuropsychiatrica, 2011, 23, 87-88.	1.0	7
302	N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. Journal of Affective Disorders, 2011, 129, 317-320.	2.0	93
303	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. Journal of Affective Disorders, 2011, 135, 389-394.	2.0	162
304	Who's left? Symptoms of schizophrenia that predict clinical trial dropout. Human Psychopharmacology, 2011, 26, 609-613.	0.7	7
305	Plasma apolipoprotein E and Alzheimer disease risk. Neurology, 2011, 76, 1091-1098.	1.5	142
306	Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.. Journal of Biological Chemistry, 2011, 286, 27068.	1.6	0

#	Article	IF	Citations
307	Presenilins Promote the Cellular Uptake of Copper and Zinc and Maintain Copper Chaperone of SOD1-dependent Copper/Zinc Superoxide Dismutase Activity. Journal of Biological Chemistry, 2011, 286, 9776-9786.	1.6	69
308	Copper Promotes the Trafficking of the Amyloid Precursor Protein. Journal of Biological Chemistry, 2011, 286, 8252-8262.	1.6	90
309	Role of amyloid-Î²â€“metal interactions in Alzheimerâ€™s disease. Future Neurology, 2011, 6, 641-659.	0.9	19
310	Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study. Dementia and Geriatric Cognitive Disorders, 2011, 31, 173-178.	0.7	115
311	Cysteine Oxidation within N-terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein. Journal of Biological Chemistry, 2011, 286, 18320-18330.	1.6	54
312	Qualitative Methods in Early-Phase Drug Trials. Journal of Clinical Psychiatry, 2011, 72, 909-913.	1.1	29
313	Plasma Amyloid-Î² as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. Journal of Alzheimer's Disease, 2010, 20, 1233-1242.	1.2	122
314	PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses. Journal of Alzheimer's Disease, 2010, 20, 509-516.	1.2	347
315	Copper in the brain and Alzheimerâ€™s disease. Journal of Biological Inorganic Chemistry, 2010, 15, 61-76.	1.1	396
316	Generation of soluble oligomeric Î²-amyloid species via copper catalyzed oxidation with implications for Alzheimerâ€™s disease: A DFT study. Journal of Molecular Modeling, 2010, 16, 1103-1108.	0.8	5
317	Serum zinc is decreased in Alzheimerâ€™s disease and serum arsenic correlates positively with cognitive ability. BioMetals, 2010, 23, 173-179.	1.8	127
318	Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain. BioMetals, 2010, 23, 1085-1095.	1.8	21
319	Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. Pharmacology Biochemistry and Behavior, 2010, 97, 293-300.	1.3	15
320	Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. European Journal of Pharmacology, 2010, 649, 224-228.	1.7	54
321	Monomerized Cu,Zn-superoxide dismutase induces oxidative stress through aberrant Cu binding. Free Radical Biology and Medicine, 2010, 48, 945-952.	1.3	11
322	A domain level interaction network of amyloid precursor protein and AÎ² of Alzheimer's disease. Proteomics, 2010, 10, 2377-2395.	1.3	41
323	Altered microglial copper homeostasis in a mouse model of Alzheimerâ€™s disease. Journal of Neurochemistry, 2010, 114, 1630-1638.	2.1	78
324	Three-dimensional elemental bio-imaging of Fe, Zn, Cu, Mn and P in a 6-hydroxydopamine lesioned mouse brain. Metallomics, 2010, 2, 745.	1.0	72

#	Article	IF	Citations
325	Tau protein: Relevance to Parkinson's disease. International Journal of Biochemistry and Cell Biology, 2010, 42, 1775-1778.	1.2	180
326	Behavioural phenotype of APPC100.V717F transgenic mice over-expressing a mutant AÎ²-bearing fragment is associated with reduced NMDA receptor density. Behavioural Brain Research, 2010, 209, 27-35.	1.2	12
327	Iron-Export Ferroxidase Activity of Î²-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease. Cell, 2010, 142, 857-867.	13.5	597
328	Insulin-like Signaling Determines Survival during Stress via Posttranscriptional Mechanisms in C. elegans. Cell Metabolism, 2010, 12, 260-272.	7.2	113
329	Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics. Progress in Neurobiology, 2010, 92, 1-18.	2.8	256
330	Kalzium Ist Nicht Alles. Neuron, 2010, 65, 143-144.	3.8	5
331	Cognitive Loss in Zinc Transporter-3 Knock-Out Mice: A Phenocopy for the Synaptic and Memory Deficits of Alzheimer's Disease?. Journal of Neuroscience, 2010, 30, 1631-1636.	1.7	327
332	Syntaxin 5 Is Required for Copper Homeostasis in Drosophila and Mammals. PLoS ONE, 2010, 5, e14303.	1.1	17
333	Pharmacotherapeutic targets in Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2009, 13, 61-86.	1.6	50
334	Paradoxical Condensation of Copper with Elevated Î²-Amyloid in Lipid Rafts under Cellular Copper Deficiency Conditions. Journal of Biological Chemistry, 2009, 284, 21899-21907.	1.6	55
335	Copper transport into the secretory pathway is regulated by oxygen in macrophages. Journal of Cell Science, 2009, 122, 1315-1321.	1.2	90
336	Increasing Cu bioavailability inhibits AÎ² oligomers and tau phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 381-386.	3.3	259
337	The Caenorhabditis elegans AÎ²1â€“42 Model of Alzheimer Disease Predominantly Expresses AÎ²3â€“42. Journal of Biological Chemistry, 2009, 284, 22697-22702.	1.6	108
338	Chronic Exposure to High Levels of Zinc or Copper has Little Effect on Brain Metal Homeostasis or AÎ² Accumulation in Transgenic APP-C100 Mice. Cellular and Molecular Neurobiology, 2009, 29, 757-767.	1.7	16
339	Enzyme solid-state support assays: a surface plasmon resonance and mass spectrometry coupled study of immobilized insulin degrading enzyme. European Biophysics Journal, 2009, 38, 407-414.	1.2	37
340	Intracellular amyloid formation in muscle cells of AÎ²-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification. Molecular Neurodegeneration, 2009, 4, 2.	4.4	39
341	Zinc in the physiology and pathology of the CNS. Nature Reviews Neuroscience, 2009, 10, 780-791.	4.9	647
342	Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial. Acta Neuropsychiatrica, 2009, 21, 285-291.	1.0	13

#	Article	IF	Citations
343	Effects of N-acetylcysteine on substance use in bipolar disorder: a randomised placebo-controlled clinical trial. Acta Neuropsychiatrica, 2009, 21, 239-245.	1.0	9
344	Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. Behavioural Brain Research, 2009, 198, 258-262.	1.2	63
345	Zinc and copper modulate Alzheimer AÎ² levels in human cerebrospinal fluid. Neurobiology of Aging, 2009, 30, 1069-1077.	1.5	126
346	Quantitative elemental bio-imaging of Mn, Fe, Cu and Zn in 6-hydroxydopamine induced Parkinsonism mouse models. Metallomics, 2009, 1, 53-58.	1.0	118
347	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 2009, 21, 672-687.	0.6	661
348	Targeting the Progression of Parkinsons Disease. Current Neuropharmacology, 2009, 7, 9-36.	1.4	69
349	A Role for Glutathione in the Pathophysiology of Bipolar Disorder and Schizophrenia? Animal Models and Relevance to Clinical Practice. Current Medicinal Chemistry, 2009, 16, 2965-2976.	1.2	81
350	Clioquinol Protects Against Cell Death in Parkinsonâ€™s Disease Models In Vivo and In Vitro. Advances in Behavioral Biology, 2009, , 431-442.	0.2	7
351	SLC30A3 Responds to Glucose- and Zinc Variations in ÃŸ-Cells and Is Critical for Insulin Production and In Vivo Glucose-Metabolism During ÃŸ-Cell Stress. PLoS ONE, 2009, 4, e5684.	1.1	75
352	Therapeutics of Alzheimerâ€™s Disease Based on Metal Bioavailability. Oxidative Stress and Disease, 2009, , .	0.3	0
353	Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis. Neurotherapeutics, 2008, 5, 421-432.	2.1	512
354	Twenty years of metallo-neurobiology: where to now?. European Biophysics Journal, 2008, 37, 241-245.	1.2	55
355	Characterization of Copper Interactions with Alzheimer Amyloid Î² Peptides. Journal of Neurochemistry, 2008, 75, 1219-1233.	2.1	566
356	Exacerbation of Copper Toxicity in Primary Neuronal Cultures Depleted of Cellular Glutathione. Journal of Neurochemistry, 2008, 72, 2092-2098.	2.1	79
357	Investigating copperâ€regulated protein expression in Menkes fibroblasts using antibody microarrays. Proteomics, 2008, 8, 1819-1831.	1.3	8
358	Sensitive, Selective, and Irreversible Inhibition of Cyclooxygenaseâ€2 Activity by Copper. ChemMedChem, 2008, 3, 223-225.	1.6	1
359	Metals in Alzheimer's and Parkinson's Diseases. Current Opinion in Chemical Biology, 2008, 12, 222-228.	2.8	640
360	Safety, efficacy, and biomarker findings of PBT2 in targeting AÎ² as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2008, 7, 779-786.	4.9	657

#	Article	IF	Citations
361	Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology, 2008, 11, 851-76.	1.0	821
362	N-Acetyl Cysteine as a Glutathione Precursor for Schizophreniaâ€"A Double-Blind, Randomized, Placebo-Controlled Trial. Biological Psychiatry, 2008, 64, 361-368.	0.7	489
363	N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorderâ€"A Double-Blind Randomized Placebo-Controlled Trial. Biological Psychiatry, 2008, 64, 468-475.	0.7	452
364	Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial AÎ². Neuron, 2008, 59, 43-55.	3.8	629
365	Glutathione: a novel treatment target in psychiatry. Trends in Pharmacological Sciences, 2008, 29, 346-351.	4.0	166
366	Mechanisms of AÎ² mediated neurodegeneration in Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2008, 40, 181-198.	1.2	220
367	Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochemical Society Transactions, 2008, 36, 1282-1287.	1.6	123
368	Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. Neuropsychopharmacology, 2008, 33, 2187-2199.	2.8	321
369	Intracellular copper deficiency increases amyloid-Î² secretion by diverse mechanisms. Biochemical Journal, 2008, 412, 141-152.	1.7	75
370	Platinum-based inhibitors of amyloid-Î² as therapeutic agents for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6813-6818.	3.3	182
371	Sequestration of Copper from Î²-Amyloid Promotes Selective Lysis by Cyclen-Hybrid Cleavage Agents. Journal of Biological Chemistry, 2008, 283, 31657-31664.	1.6	109
372	Insights into Zn²⁺homeostasis in neurons from experimental and modeling studies. American Journal of Physiology - Cell Physiology, 2008, 294, C726-C742.	2.1	184
373	Drug Development Based on the Metals Hypothesis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 223-240.	1.2	250
374	Specific Metal-Catalysed Protein Oxidation Reactions in Chronic Degenerative Disorders of Ageing: Focus on Alzheimer's Disease and Age-Related Cataracts. Novartis Foundation Symposium, 2008, 235, 26-43.	1.2	15
375	Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience, 2007, 150, 357-369.	1.1	110
376	Metal Ions and Alzheimer's Disease. , 2007, , 333-361.		0
377	Mitochondria in Aging and Alzheimer's Disease. Rejuvenation Research, 2007, 10, 349-358.	0.9	50
378	Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau. PLoS ONE, 2007, 2, e536.	1.1	291

#	Article	IF	Citations
379	The modulation of metal bioâ€availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS Journal, 2007, 274, 3775-3783.	2.2	66
380	Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2007, 42, 1534-1542.	1.3	47
381	Metal Complexing Agents for the Treatment of Alzheimer's Disease. , 2007, , 107-136.		2
382	AÎ² Structure and Aggregation. , 2007, , 113-131.		1
383	Free Radicals, Metal Ions, and AÎ² Aggregation and Neurotoxicity. , 2007, , 31-47.		4
384	Mechanisms of Copper Ion Mediated Huntington's Disease Progression. PLoS ONE, 2007, 2, e334.	1.1	159
385	Elevated cortical zinc in Alzheimer disease. Neurology, 2006, 67, 69-75.	1.5	235
386	Neurodegenerative Diseases and Metal Ions. A Concluding Overview. , 2006, , 427-435.		2
387	The Role of Metal Ions in Neurology. An Introduction. , 2006, , 1-7.		7
388	Metals and Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 10, 145-163.	1.2	306
389	Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn2+ complexes in Alzheimer's disease. Aging Cell, 2006, 5, 69-79.	3.0	74
390	Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: Implications for Alzheimer Î²-amyloid pathology. Journal of Inorganic Biochemistry, 2006, 100, 952-962.	1.5	93
391	RNA Therapeutics Directed to the Non Coding Regions of APP mRNA, In Vivo Anti-Amyloid Efficacy of Paroxetine, Erythromycin, and N-acetyl cysteine. Current Alzheimer Research, 2006, 3, 221-227.	0.7	48
392	Degradation of the Alzheimer Disease Amyloid Î²-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity. Journal of Biological Chemistry, 2006, 281, 17670-17680.	1.6	267
393	Metal homeostasis in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2006, 6, 711-722.	1.4	39
394	Copper-mediated Amyloid-Î² Toxicity Is Associated with an Intermolecular Histidine Bridge*. Journal of Biological Chemistry, 2006, 281, 15145-15154.	1.6	170
395	Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Drug News and Perspectives, 2006, 19, 469.	1.9	37
396	Alzheimer disease Â-amyloid activity mimics cholesterol oxidase. Journal of Clinical Investigation, 2006, 116, 2828-2828.	3.9	1

#	Article	IF	Citations
397	Amyloid-Î² Metal Interaction and Metal Chelation. , 2005, 38, 235-254.		62
398	Model studies of cholesterol and ascorbate oxidation by copper complexes: Relevance to Alzheimerâ€™s disease Î²-amyloid metallochemistry. Journal of Inorganic Biochemistry, 2005, 99, 2403-2422.	1.5	36
399	Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition. Journal of Biological Chemistry, 2005, 280, 41732-41743.	1.6	265
400	The neurobiology of zinc in health and disease. Nature Reviews Neuroscience, 2005, 6, 449-462.	4.9	1,633
401	Metals and amyloid-Î² in Alzheimer's disease. International Journal of Experimental Pathology, 2005, 86, 147-159.	0.6	303
402	Mice transgenic for Alzheimer disease ?-amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Radical Biology and Medicine, 2005, 38, 258-261.	1.3	77
403	Methionine regulates copper/hydrogen peroxide oxidation products of AÎ². Journal of Peptide Science, 2005, 11, 353-360.	0.8	88
404	Copper and zinc in Alzheimer's disease and amyotrophic lateral sclerosis. , 2005, , 157-165.		0
405	Pilot Study of the Reducing Effect on Amyloidosis In Vivo by Three FDA Pre-Approved Drugs Via the Alzheimers APP 5Untranslated Region. Current Alzheimer Research, 2005, 2, 249-254.	0.7	38
406	Methylation of the Imidazole Side Chains of the Alzheimer Disease Amyloid-Î² Peptide Results in Abolition of Superoxide Dismutase-like Structures and Inhibition of Neurotoxicity. Journal of Biological Chemistry, 2005, 280, 13355-13363.	1.6	110
407	Alzheimer disease Î²-amyloid activity mimics cholesterol oxidase. Journal of Clinical Investigation, 2005, 115, 2556-2563.	3.9	125
408	Methionine Sulfoxide Reductase System. Oxidative Stress and Disease, 2005, , 199-212.	0.3	0
409	Metal-Protein Attenuating Compounds (MPACs) for the Treatment of Alzheimers Disease. Drug Design Reviews Online, 2004, 1, 75-82.	0.7	9
410	Neuronal Zinc Exchange with the Blood Vessel Wall Promotes Cerebral Amyloid Angiopathy in an Animal Model of Alzheimer's Disease. Journal of Neuroscience, 2004, 24, 3453-3459.	1.7	135
411	The Nâ€terminal copperâ€binding domain of the amyloid precursor protein protects against Cu 2+ neurotoxicity in vivo. FASEB Journal, 2004, 18, 1701-1703.	0.2	40
412	Enhanced Toxicity and Cellular Binding of a Modified Amyloid Î² Peptide with a Methionine to Valine Substitution. Journal of Biological Chemistry, 2004, 279, 42528-42534.	1.6	99
413	Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease Î²â€amyloid. FASEB Journal, 2004, 18, 1427-1429.	0.2	251
414	Serum Copper. Archives of Neurology, 2004, 61, 631.	4.9	13

#	Article	IF	Citations
415	Genetically Decreased Spinal Cord Copper Concentration Prolongs Life in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2004, 24, 7945-7950.	1.7	50
416	Estrogen Decreases Zinc Transporter 3 Expression and Synaptic Vesicle Zinc Levels in Mouse Brain. Journal of Biological Chemistry, 2004, 279, 8602-8607.	1.6	80
417	Neurodegenerative diseases and oxidative stress. Nature Reviews Drug Discovery, 2004, 3, 205-214.	21.5	2,923
418	Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Experimental Gerontology, 2004, 39, 1641-1649.	1.2	131
419	Redox-Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology. Annals of the New York Academy of Sciences, 2004, 1012, 153-163.	1.8	381
420	The Integrated Role of Desferrioxamine and Phenserine Targeted to an Iron-Responsive Element in the APP-mRNA 5'-Untranslated Region. Annals of the New York Academy of Sciences, 2004, 1035, 34-48.	1.8	52
421	Iron inhibits neurotoxicity induced by trace copper and biological reductants. Journal of Biological Inorganic Chemistry, 2004, 9, 269-280.	1.1	42
422	Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer?s A? peptides. Journal of Biological Inorganic Chemistry, 2004, 9, 954-960.	1.1	218
423	Characterizing bathocuproine self-association and subsequent binding to Alzheimer's disease amyloidÎ²-peptide by NMR. Journal of Peptide Science, 2004, 10, 210-217.	0.8	24
424	Metal-protein attenuating compounds and Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2004, 13, 1585-1592.	1.9	60
425	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-Î². Biochemistry, 2004, 43, 560-568.	1.2	362
426	Peroxidase Activity of Cyclooxygenase-2 (COX-2) Cross-links Î²-Amyloid (AÎ²) and Generates AÎ²-COX-2 Hetero-oligomers That Are Increased in Alzheimer's Disease. Journal of Biological Chemistry, 2004, 279, 14673-14678.	1.6	44
427	P3-187 Mutagenesis-toxicity studies of the amyloid beta peptide of Alzheimer's disease. Neurobiology of Aging, 2004, 25, S409.	1.5	0
428	P4-241 The mechanism by which AÎ² produces hydrogen peroxide and its role in neurotoxicity. Neurobiology of Aging, 2004, 25, S544.	1.5	1
429	P4-402 Alzheimer's disease drug discovery targeted to the APP MRNA 5â€² untranslated region, a validated target. Neurobiology of Aging, 2004, 25, S589.	1.5	0
430	Alzheimerâ€™s amyloid Î²-peptide (1â€“42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiology of Aging, 2004, 25, 563-568.	1.5	129
431	S4-02-06 Copper and zinc in Alzheimer's disease: from bench to clinic. Neurobiology of Aging, 2004, 25, S69-S70.	1.5	0
432	P1-131 (AÎ²) in human lens & aqueous humor: further characterization of a novel AD biomarker. Neurobiology of Aging, 2004, 25, S135-S136.	1.5	0

#	Article	IF	Citations
433	Methionine oxidation: Implications for the mechanism of toxicity of the Î²-amyloid peptide from Alzheimer's disease. International Journal of Peptide Research and Therapeutics, 2003, 10, 413-417.	0.1	13
434	Beta-amyloid cuproprotein: a therapeutic target for alzheimer's disease. Journal of Inorganic Biochemistry, 2003, 96, 43.	1.5	0
435	Current Status of Metals as Therapeutic Targets in Alzheimer's Disease. Journal of the American Geriatrics Society, 2003, 51, 1143-1148.	1.3	198
436	Methionine oxidation: Implications for the mechanism of toxicity of the Î²-amyloid peptide from Alzheimer's disease. International Journal of Peptide Research and Therapeutics, 2003, 10, 413-417.	0.9	6
437	Cytosolic Î²-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet, The, 2003, 361, 1258-1265.	6.3	323
438	The metallobiology of Alzheimer's disease. Trends in Neurosciences, 2003, 26, 207-214.	4.2	1,191
439	Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo. Neuron, 2003, 37, 899-909.	3.8	594
440	Metal Ions, pH, and Cholesterol Regulate the Interactions of Alzheimer's Disease Amyloid-Î² Peptide with Membrane Lipid. Journal of Biological Chemistry, 2003, 278, 2977-2982.	1.6	190
441	Copper, Â-amyloid, and Alzheimer's disease: Tapping a sensitive connection. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11193-11194.	3.3	134
442	Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting AÎ² Amyloid Deposition and Toxicity in Alzheimer Disease. Archives of Neurology, 2003, 60, 1685.	4.9	951
443	Neurotoxic, Redox-competent Alzheimer's Î²-Amyloid Is Released from Lipid Membrane by Methionine Oxidation. Journal of Biological Chemistry, 2003, 278, 42959-42965.	1.6	176
444	BIOMEDICINE: To Write a Book, To Plant a Tree.... Science, 2003, 299, 1318-1319.	6.0	1
445	Copper, Zinc, and the Metallobiology of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2003, 17, 147-150.	0.6	103
446	Importance of Copper and Zinc in Alzheimer's Disease and the Biology of Amyloid-Î² Protein and Amyloid-Î² Protein Precursor. , 2003, , 245-261.		0
447	The galvanization of Â-amyloid in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7317-7319.	3.3	127
448	Overexpression of Alzheimer's Disease Amyloid-Î² Opposes the Age-dependent Elevations of Brain Copper and Iron. Journal of Biological Chemistry, 2002, 277, 44670-44676.	1.6	324
449	Metalloenzyme-like Activity of Alzheimer's Disease Î²-Amyloid. Journal of Biological Chemistry, 2002, 277, 40302-40308.	1.6	536
450	An Iron-responsive Element Type II in the 5â€²-Untranslated Region of the Alzheimer's Amyloid Precursor Protein Transcript. Journal of Biological Chemistry, 2002, 277, 45518-45528.	1.6	474

#	Article	IF	Citations
451	Metal complexing agents as therapies for Alzheimerâ€™s disease. Neurobiology of Aging, 2002, 23, 1031-1038.	1.5	303
452	Response: â€˜â€¦and C is for Clioquinolâ€™ â€“ the AÎ²Cs of Alzheimer's disease. Trends in Neurosciences, 2002, 25, 123-124.	4.2	1
453	Alzheimerâ€™s disease drug discovery targeted to the APP mRNA 5â€²Untranslated region. Journal of Molecular Neuroscience, 2002, 19, 77-82.	1.1	58
454	Intracellular Accumulation of Detergent-Soluble Amyloidogenic AÎ² Fragment of Alzheimer's Disease Precursor Protein in the Hippocampus of Aged Transgenic Mice. Journal of Neurochemistry, 2002, 72, 2479-2487.	2.1	74
455	Is ALS caused by an altered oxidative activity of mutant superoxide dismutase?. Nature Neuroscience, 2002, 5, 919-919.	7.1	29
456	Copper, Zinc, and Alzheimerâ€™s Disease. , 2002, , 229-239.		0
457	Copper and Zinc Binding Modulates the Aggregation and Neurotoxic Properties of the Prion Peptide PrP106â€“126. Biochemistry, 2001, 40, 8073-8084.	1.2	264
458	Clioquinol's Return: Cautions from Japan. Science, 2001, 292, 2251-2252.	6.0	33
459	Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits Î²-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice. Neuron, 2001, 30, 665-676.	3.8	1,419
460	Alzheimer's Disease Amyloid-Î² Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits. Journal of Biological Chemistry, 2001, 276, 20466-20473.	1.6	595
461	Therapeutic targets in the biology of AlzheimerÊ¼s disease. Current Opinion in Psychiatry, 2001, 14, 341-348.	3.1	14
462	Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. Journal of Neurochemistry, 2001, 76, 1509-1520.	2.1	228
463	Synaptically released zinc: physiological functions and pathological effects. BioMetals, 2001, 14, 353-366.	1.8	332
464	Redox-active iron mediates amyloid-Î² toxicity. Free Radical Biology and Medicine, 2001, 30, 447-450.	1.3	356
465	Computerised cognitive assessment of concussed Australian Rules footballers. British Journal of Sports Medicine, 2001, 35, 354-360.	3.1	133
466	Synaptically released zinc: Physiological functions and pathological effects. , 2001, , 167-180.		2
467	N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. NeuroReport, 2000, 11, 2491-2493.	0.6	128
468	Metals and neuroscience. Current Opinion in Chemical Biology, 2000, 4, 184-191.	2.8	695

#	Article	IF	Citations
469	Oxidative processes in Alzheimer's disease: the role of AÎ²-metal interactions. Experimental Gerontology, 2000, 35, 445-451.	1.2	145
470	Alzheimer's Disease, Î²-Amyloid Protein and Zinc. Journal of Nutrition, 2000, 130, 1488S-1492S.	1.3	102
471	Could AÃŸ and AÃŸPP be Antioxidants?. Journal of Alzheimer's Disease, 2000, 2, 83-84.	1.2	9
472	Evidence that the Î²-Amyloid Plaques of Alzheimer's Disease Represent the Redox-silencing and Entombment of AÎ² by Zinc. Journal of Biological Chemistry, 2000, 275, 19439-19442.	1.6	366
473	Chelation and Intercalation: Complementary Properties in a Compound for the Treatment of Alzheimer's Disease. Journal of Structural Biology, 2000, 130, 209-216.	1.3	81
474	3-Hydroxykynurenine and 3-Hydroxyanthranilic Acid Generate Hydrogen Peroxide and Promote Î±-Crystallin Cross-Linking by Metal Ion Reductionâ€. Biochemistry, 2000, 39, 7266-7275.	1.2	183
475	Metal Chelation as a Potential Therapy for Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 920, 292-304.	1.8	178
476	Copper catalyzed oxidation of Alzheimer Abeta. Cellular and Molecular Biology, 2000, 46, 777-83.	0.3	58
477	The Alzheimer's Disease Amyloid Precursor Protein Modulates Copper-Induced Toxicity and Oxidative Stress in Primary Neuronal Cultures. Journal of Neuroscience, 1999, 19, 9170-9179.	1.7	213
478	Mounting evidence for the involvement of zinc and copper in Alzheimer's disease. European Journal of Clinical Investigation, 1999, 29, 569-570.	1.7	21
479	Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Research, 1999, 842, 439-444.	1.1	279
480	Soluble pool of A? amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Annals of Neurology, 1999, 46, 860-866.	2.8	1,721
481	Aqueous Dissolution of Alzheimer's Disease AÎ² Amyloid Deposits by Biometal Depletion. Journal of Biological Chemistry, 1999, 274, 23223-23228.	1.6	454
482	The AÎ² Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reductionâ€. Biochemistry, 1999, 38, 7609-7616.	1.2	1,098
483	Cu(II) Potentiation of Alzheimer AÎ² Neurotoxicity. Journal of Biological Chemistry, 1999, 274, 37111-37116.	1.6	688
484	Zinc and Alzheimer's Disease: An Update. Nutritional Neuroscience, 1999, 2, 191-208.	1.5	7
485	Differential Effects of Apolipoprotein E Isoforms on Metal-Induced Aggregation of AÎ² Using Physiological Concentrationsâ€. Biochemistry, 1999, 38, 4595-4603.	1.2	125
486	Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Metal Ions in Biological Systems, 1999, 36, 309-64.	0.4	63

#	Article	IF	Citations
487	Î²-Amyloid augments platelet aggregation: reduced activity of familial angiopathy-associated mutants. Molecular Psychiatry, 1998, 3, 500-507.	4.1	14
488	Potential therapeutic targets for Alzheimerâ€™s disease. Expert Opinion on Therapeutic Targets, 1998, 2, 157-179.	1.0	6
489	Relative Increase in Alzheimer's Disease of Soluble Forms of Cerebral AÎ² Amyloid Protein Precursor Containing the Kunitz Protease Inhibitory Domain. Journal of Biological Chemistry, 1998, 273, 5013-5019.	1.6	95
490	Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid Î²-Peptide in Alzheimerâ€™s Disease and Major Depression â€“ Inverse Correlation with Dementia Severity. European Neurology, 1998, 39, 111-118.	0.6	77
491	Dramatic Aggregation of Alzheimer AÎ² by Cu(II) Is Induced by Conditions Representing Physiological Acidosis. Journal of Biological Chemistry, 1998, 273, 12817-12826.	1.6	935
492	Alzheimer Disease-Related Abnormalities of Amyloid beta Precursor Protein Isoforms in the Platelet: The Brain's Delegate in the Periphery?. Archives of Neurology, 1998, 55, 1179-1180.	4.9	35
493	Zinc-induced Alzheimer's AÎ²1â€“40 Aggregation Is Mediated by Conformational Factors. Journal of Biological Chemistry, 1997, 272, 26464-26470.	1.6	287
494	Metallothioneins in Brainâ€”The Role in Physiology and Pathology. Toxicology and Applied Pharmacology, 1997, 142, 229-242.	1.3	182
495	Cerebral Zinc Metabolism in Alzheimerâ€™s Disease. , 1997, , 225-237.		4
496	Response. Science, 1995, 268, 1921-1923.	6.0	63
497	LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted Î²-amyloid precursor protein and mediates its degradation. Cell, 1995, 82, 331-340.	13.5	499
498	Genetic studies of Alzheimer's disease: Lessons learned and future imperatives. Neurobiology of Aging, 1994, 15, 145-148.	1.5	4
499	Rapid induction of Alzheimer A beta amyloid formation by zinc. Science, 1994, 265, 1464-1467.	6.0	1,521
500	Interaction between the zinc(II) and the heparin binding site of the Alzheimer's disease Î²A4 amyloid precursor protein (APP). FEBS Letters, 1994, 355, 151-154.	1.3	86
501	The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily.. Journal of Biological Chemistry, 1994, 269, 26618-26621.	1.6	105
502	The Roles of Zinc and Copper in the Function and Metabolism of the Amyloid Protein Precursor Superfamily. , 1994, , 169-180.		0
503	The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. Journal of Biological Chemistry, 1994, 269, 26618-21.	1.6	89
504	Modulation of A beta adhesiveness and secretase site cleavage by zinc. Journal of Biological Chemistry, 1994, 269, 12152-8.	1.6	230

#	Article	IF	Citations
505	The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nature Genetics, 1993, 5, 344-350.	9.4	1,307
506	Genetic heterogeneity of gene defects responsible for familial Alzheimer disease. Genetica, 1993, 91, 255-263.	0.5	28
507	The Î²A4 Amyloid Protein Precursor in Human Circulationa. Annals of the New York Academy of Sciences, 1993, 695, 175-182.	1.8	15
508	A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. Journal of Biological Chemistry, 1993, 268, 16109-12.	1.6	220
509	Î² A4 amyloid protein and its precursor in Alzheimer's disease. , 1992, 56, 97-117.		32
510	The abnormality of plasma amyloid protein precursor in Alzheimer's disease. Neurobiology of Aging, 1992, 13, S29.	1.5	0
511	Human Brain ?A4 Amyloid Protein Precursor of Alzheimer's Disease: Purification and Partial Characterization. Journal of Neurochemistry, 1992, 59, 1490-1498.	2.1	49
512	Specific binding of the alzheimer Î²A4 amyloid precursor to collagen, laminin, and heparin. The Protein Journal, 1992, 11, 398-399.	1.1	22
513	An abnormality of plasma amyloid protein precursor in Alzheimer's disease. Annals of Neurology, 1992, 32, 57-65.	2.8	56
514	A protease activity associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer's disease. Biochemistry, 1991, 30, 10795-10799.	1.2	78
515	Mechanisms of Amyloid Deposition in Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1991, 640, 129-139.	1.8	57
516	Hypothalamic Atrial Natriuretic Peptide Secretion Plasticity: Differential Modulation of Alpha and Beta Adrenoceptors. Neuroendocrinology, 1990, 52, 65-69.	1.2	13
517	The Î²A4 amyloid protein and its precursors as biological markers for Alzheimer's disease. Neurobiology of Aging, 1990, 11, 330-331.	1.5	0
518	The amyloid precursor protein of Alzheimer's disease is released by human platelets. Journal of Biological Chemistry, 1990, 265, 15977-83.	1.6	236
519	Parallels between the Redox Properties and Toxicity of AÎ² in Alzheimer's Disease and Mutant Cu/Zn-SOD in Familial Amyotrophic Lateral Sclerosis. , 0, , 393-406.		0
520	Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-translational Modification of Amyloid Deposits. , 0, , 341-361.		14